High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides

Nucleic Acids Research

Volumn 43, Issue 4, 2015, Pages 1987-1996

  Yang, B ^a   Ming, X ^a   Cao, C ^a   Laing, B ^a   Yuan, A ^a   Porter, M A ^a   Hull Ryde, E A ^a   Maddry, J ^b   Suto, M ^b   Janzen, W P ^a   Juliano, R L ^a  

^a University of North Carolina   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MOLECULAR LIBRARY; OLIGONUCLEOTIDE; SMALL INTERFERING RNA;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; HIGH THROUGHPUT SCREENING; HUMAN; INTRACELLULAR MEMBRANE; MOLECULAR LIBRARY; MOUSE; PHARMACOLOGY; TOXICITY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; DRUG SYNERGISM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTRACELLULAR MEMBRANES; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES;

EID: 84941075059     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv060     Document Type: Article

References (70)

1. Bennett, C.F., Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
2. Kole, R., Krainer, A.R., Altman, S. (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov., 11, 125-140.
3. Burnett, J.C., Rossi, J.J. (2012) RNA-based therapeutics: current progress and future prospects. Chem. Biol., 19, 60-71.
4. Wu, S.Y., Lopez-Berestein, G., Calin, G.A., Sood, A.K. (2014) RNAi therapies: drugging the undruggable. Sci. Transl. Med., 6, 240-247.
5. Watts, J.K., Corey, D.R. (2011) Silencing disease genes in the laboratory and the clinic. J. Pathol., 226, 365-379.
6. Tse, M.T. (2013) Regulatory watch: antisense approval provides boost to field. Nat. Rev. Drug Discov., 12, 179.
7. Bianchini, D., Omlin, A., Pezaro, C., Lorente, D., Ferraldeschi, R., Mukherji, D., Crespo, M., Figueiredo, I., Miranda, S., Riisnaes, R. et al. (2013) First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br. J. Cancer, 109, 2579-2586.
8. Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P.N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E. et al. (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med., 369, 819-829.
9. Koo, T., Wood, M.J. (2013) Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum. Gene Ther., 24, 479-488.
10. Juliano, R., Bauman, J., Kang, H., Ming, X. (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm., 6, 686-695.
11. Whitehead, K.A., Langer, R., Anderson, D.G. (2009) Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 8, 129-138.
12. Varkouhi, A.K., Scholte, M., Storm, G., Haisma, H.J. (2011) Endosomal escape pathways for delivery of biologicals. Journal of controlled release : official journal of the Controlled Release Society, 151, 220-228.
13. Pallan, P.S., Allerson, C.R., Berdeja, A., Seth, P.P., Swayze, E.E., Prakash, T.P., Egli, M. (2012) Structure and nuclease resistance of 2-, 4-constrained 2-O-methoxyethyl (cMOE) and 2-O-ethyl (cEt) modified DNAs. Chem Commun (Camb), 48, 8195-8197.
14. Campbell, M.A., Wengel, J. (2011) Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chemical Society reviews, 40, 5680-5689.
15. Davis, M.E., Zuckerman, J.E., Choi, C.H., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D., Ribas, A. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 464, 1067-1070.
16. Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D. (2013) Delivery materials for siRNA therapeutics. Nature materials, 12, 967-977.
17. Li, J., Huang, L. (2010) Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine, 5, 1483-1486.
18. Li, J., Wang, Y., Zhu, Y., Oupicky, D. (2013) Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J. Control. Release, 172, 589-600.
19. Tamura, A., Nagasaki, Y. (2010) Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine, 5, 1089-1102.
20. Musacchio, T., Torchilin, V.P. (2013) siRNA delivery: from basics to therapeutic applications. Fron. Biosci., 18, 58-79.
21. Nguyen, J., Szoka, F.C. (2012) Nucleic acid delivery: the missing pieces of the puzzle? Acc. Chem. Res., 45, 1153-1162.
22. Deshayes, S., Konate, K., Rydstrom, A., Crombez, L., Godefroy, C., Milhiet, P.E., Thomas, A., Brasseur, R., Aldrian, G., Heitz, F. et al. (2012) Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines. Small, 8, 2184-2188.
23. van Asbeck, A.H., Beyerle, A., McNeill, H., Bovee-Geurts, P.H., Lindberg, S., Verdurmen, W.P., Hallbrink, M., Langel, U., Heidenreich, O., Brock, R. (2013) Molecular parameters of siRNA-cell penetrating peptide nanocomplexes for efficient cellular delivery. ACS Nano, 7, 3797-3807.
24. Alam, M.R., Dixit, V., Kang, H., Li, Z.B., Chen, X., Trejo, J., Fisher, M., Juliano, R.L. (2008) Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res., 36, 2764-2776.
25. Alam, M.R., Ming, X., Fisher, M., Lackey, J.G., Rajeev, K.G., Manoharan, M., Juliano, R.L. (2011) Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. Bioconjug. Chem., 22, 1673-1681.
26. Ming, X., Alam, M.R., Fisher, M., Yan, Y., Chen, X., Juliano, R.L. (2010) Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res., 38, 6567-6576.
27. Ming, X., Carver, K., Wu, L. (2013) Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. Biomaterials, 34, 7939-7949.
28. Nakagawa, O., Ming, X., Carver, K., Juliano, R. (2014) Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides. Bioconjug. Chem., 25, 165-170.
29. Nakagawa, O., Ming, X., Huang, L., Juliano, R.L. (2010) Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J. Am. Chem. Soc., 132, 8848-8849.
30. Dassie, J.P., Liu, X.Y., Thomas, G.S., Whitaker, R.M., Thiel, K.W., Stockdale, K.R., Meyerholz, D.K., McCaffrey, A.P., McNamara, J.O. 2nd and Giangrande, P.H. (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol., 27, 839-849.
31. Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C. et al. (2009) In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol., 27, 925-932.
32. Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K.N., Jayaraman, M., Rajeev, K.G., Cantley, W.L., Dorkin, J.R. et al. (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther., 18, 1357-1364.
33. Sethi, D., Chen, C.P., Jing, R.Y., Thakur, M.L., Wickstrom, E. (2012) Fluorescent peptide-PNA chimeras for imaging monoamine oxidase A mRNA in neuronal cells. Bioconjug. Chem., 23, 158-163.
34. Nielsen, C., Kjems, J., Sorensen, K.R., Engelholm, L.H., Behrendt, N. (2014) Advances in targeted delivery of small interfering RNA using simple bioconjugates. Expert Opin. Drug Deliv., 11, 791-822.
35. Maeda, H., Nakamura, H., Fang, J. (2013) The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev., 65, 71-79.
36. Akhtar, S. (2010) Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics. Expert Opin. Drug Metab. Toxicol., 6, 1347-1362.
37. Xue, H.Y., Liu, S., Wong, H.L. (2014) Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine, 9, 295-312.
38. Xu, S., Olenyuk, B.Z., Okamoto, C.T., Hamm-Alvarez, S.F. (2013) Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv. Drug Deliv. Rev., 65, 121-138.
39. Juliano, R.L., Ming, X., Nakagawa, O. (2012) Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug. Chem., 23, 147-157.
40. Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stoter, M. et al. (2013) Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol., 31, 638-646.
41. Mellman, I., Emr, S.D. (2013) A Nobel Prize for membrane traffic: vesicles find their journey's end. J. Cell Biol., 203, 559-561.
42. Doherty, G.J., McMahon, H.T. (2009) Mechanisms of endocytosis. Annu. Rev. Biochem., 78, 857-902.
43. Pfeffer, S.R. (2013) Rab GTPase regulation of membrane identity. Curr. Opin. Cell Biol., 25, 414-419.
44. Cai, H., Reinisch, K., Ferro-Novick, S. (2007) Coats, tethers, Rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle. Dev. Cell, 12, 671-682.
45. Henne, W.M., Buchkovich, N.J., Emr, S.D. (2011) The ESCRT pathway. Dev. Cell, 21, 77-91.
46. Johannes, L., Wunder, C. (2011) Retrograde transport: two (or more) roads diverged in an endosomal tree? Traffic, 12, 956-962.
47. Alam, M.R., Ming, X., Dixit, V., Fisher, M., Chen, X., Juliano, R.L. (2009) The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides, 20, 103-109.
48. Koller, E., Vincent, T.M., Chappell, A., De, S., Manoharan, M., Bennett, C.F. (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res., 39, 4795-4807.
49. Lehto, T., Castillo Alvarez, A., Gauck, S., Gait, M.J., Coursindel, T., Wood, M.J., Lebleu, B., Boisguerin, P. (2014) Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res., 42, 3207-3217.
50. Mescalchin, A., Detzer, A., Wecke, M., Overhoff, M., Wunsche, W., Sczakiel, G. (2007) Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery. Expert Opin. Biol. Ther., 7, 1531-1538.
51. von Kleist, L., Haucke, V. (2012) At the crossroads of chemistry and cell biology: inhibiting membrane traffic by small molecules. Traffic, 13, 495-504.
52. Stechmann, B., Bai, S.K., Gobbo, E., Lopez, R., Merer, G., Pinchard, S., Panigai, L., Tenza, D., Raposo, G., Beaumelle, B. et al. (2010) Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell, 141, 231-242.
53. Ming, X., Carver, K., Fisher, M., Noel, R., Cintrat, J.C., Gillet, D., Barbier, J., Cao, C., Bauman, J., Juliano, R.L. (2013) The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res., 41, 3673-3687.
54. Bauman, J.A., Li, S.D., Yang, A., Huang, L., Kole, R. (2010) Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res., 38, 8348-8356.
55. Wigle, T.J., Herold, J.M., Senisterra, G.A., Vedadi, M., Kireev, D.B., Arrowsmith, C.H., Frye, S.V., Janzen, W.P. (2010) Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. J. Biomol. Screen., 15, 62-71.
56. Hutti, J.E., Porter, M.A., Cheely, A.W., Cantley, L.C., Wang, X., Kireev, D., Baldwin, A.S., Janzen, W.P. (2012) Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKepsilon. PLoS One, 7, e41494.
57. Kireev, D., Wigle, T.J., Norris-Drouin, J., Herold, J.M., Janzen, W.P., Frye, S.V. (2010) Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds. J. Med. Chem., 53, 7625-7631.
58. Peterson, E.J., Janzen, W.P., Kireev, D., Singleton, S.F. (2012) High-throughput screening for RecA inhibitors using a transcreener adenosine 5-O-diphosphate assay. Assay Drug Dev. Technol., 10, 260-268.
59. Fisher, M., Abramov, M., Van Aerschot, A., Xu, D., Juliano, R.L., Herdewijn, P. (2007) Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res., 35, 1064-1074.
60. Ming, X., Ju, W., Wu, H., Tidwell, R.R., Hall, J.E., Thakker, D.R. (2009) Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab. Dispos., 37, 424-430.
61. Dunn, K.W., Kamocka, M.M., McDonald, J.H. (2011) A practical guide to evaluating colocalization in biological microscopy. Am. J. Physiol. Cell Physiol., 300, C723-C742.
62. Sazani, P., Gemignani, F., Kang, S.H., Maier, M.A., Manoharan, M., Persmark, M., Bortner, D., Kole, R. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol., 20, 1228-1233.
63. Roberts, J., Palma, E., Sazani, P., Orum, H., Cho, M., Kole, R. (2006) Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol. Ther., 14, 471-475.
64. Zinchuk, V., Grossenbacher-Zinchuk, O. (2011) Quantitative colocalization analysis of confocal fluorescence microscopy images. Curr. Protoc. Cell Biol., doi:10.1002/0471143030.cb0419s52.
65. Corish, P., Tyler-Smith, C. (1999) Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng., 12, 1035-1040.
66. Kudla, G., Lipinski, L., Caffin, F., Helwak, A., Zylicz, M. (2006) High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol., 4, e180.
67. Midoux, P., Pichon, C., Yaouanc, J.J., Jaffres, P.A. (2009) Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol., 157, 166-178.
68. Bissig, C., Gruenberg, J. (2013) Lipid sorting and multivesicular endosome biogenesis. Cold Spring Harb. Perspect. Biol., 5, a016816.
69. Dowling, J.K., O'Neill, L.A. (2012) Biochemical regulation of the inflammasome. Crit. Rev. Biochem. Mol. Biol., 47, 424-443.
70. Suling, W.J., Maddry, J.A. (2001) Antimycobacterial activity of 1-deaza-7, 8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro. J. Antimicrob. Chemother., 47, 451-454.